Population Pharmacokinetic Evaluation of a Fully Human IgG2 Monoclonal Antibody in Patients with Inflammatory Diseases

E-ISSN： 2212-4055|9|4|229-237

ISSN： 1871-5281

Source： Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol.9, Iss.4, 2010-09, pp. : 229-237

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Conversion of TBAb Response to TSAb Response by Anti-human IgG Antibody

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 13, Iss. 4, 2013-12 ,pp. : 311-315

Bentham Science Publishers

Access to resources Recommend Favorite

Refinement of the Population Pharmacokinetic Model for the Monoclonal Antibody Matuzumab: External Model Evaluation and Simulations

By Kuester Katharina Kovar Andreas Lüpfert Christian Brockhaus Brigitte Kloft Charlotte

Clinical Pharmacokinetics, Vol. 48, Iss. 7, 2009-07 ,pp. : 477-487

Adis International

Access to resources Recommend Favorite

Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours

By Humblet Yves

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 7, 2004-07 ,pp. : 1621-1633

Informa Healthcare

Access to resources Recommend Favorite

Novel anti-IgE monoclonal antibody promising against allergic diseases

Inpharma, Vol. 1, Iss. 1232, 2000-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Effect of pH and Excipients on Structure, Dynamics, and Long-Term Stability of a Model IgG1 Monoclonal Antibody upon Freeze-Drying

By Park Jihea Nagapudi Karthik Vergara Camille Ramachander Ranjini Laurence Jennifer Krishnan Sampathkumar

Pharmaceutical Research, Vol. 30, Iss. 4, 2013-04 ,pp. : 968-984

Springer Publishing Company

Access to resources Recommend Favorite